At what enterprise value was NUTRISENS acquired in 2025?

During the acquisition of NUTRISENS by CINVEN in 2025, the transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b EUR.

What was the EV/EBITDA of NUTRISENS when it was acquired by CINVEN?

The estimated EV/EBITDA multiple for NUTRISENS is in the range of 15x - 25x.

When was NUTRISENS acquired by CINVEN?

NUTRISENS was acquired by CINVEN in 2025.

What was the revenue of NUTRISENS at the time of the deal?

The revenue of NUTRISENS at the time of the deal is estimated to be in the range of 100M - 200M EUR.

What was the EBITDA of NUTRISENS during the acquisition?

NUTRISENS's EBITDA is estimated to be in the range of 25M - 50M EUR.

How is the data for the NUTRISENS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the NUTRISENS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/cinven-valorise-nutrisens-plus-de-700-meur-2166369

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaNUTRISENS

04/2025

NUTRISENS acquired by CINVEN

FRANCE Life Sciences / Nutrition & Dietary Supplements EV 500M - 1.5b EUR

Context

Cinven acquires a majority stake in the French clinical nutrition group Nutrisens from Sagard. The transaction values the company at over EUR700 million. Under Sagard's tenure, Nutrisens tripled its size through organic growth and acquisitions. With Cinven's backing, the group aims to become a global platform in the fragmented medical nutrition market, targeting further acquisitions in Europe and expanding into new therapeutic areas.

In the past, the company underwent an LBO led by Sagard in 2021, and continued an active consolidation strategy by notably acquiring Prodiet (2025).

NUTRISENS, which reported an EBITDA margin of in 2024, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

A leading European specialist in clinical nutrition and "medical food". Founded in 2011, the group develops specific nutritional products for patients suffering from pathologies such as dysphagia (swallowing difficulties), malnutrition, or renal failure. It serves hospitals, nursing homes (EHPAD), and pharmacies. The group has a strong Corporate footprint in France and Spain.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Other operations with NUTRISENS

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
03/2025	NUTRISENS	PRODIET	BRAZIL	Nutrition & Dietary Supplements
01/2021	SAGARD	NUTRISENS	FRANCE	Nutrition & Dietary Supplements

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 100M - 200M EUR

EBITDA range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NUTRISENS by CINVEN are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: cinven